Ontology highlight
ABSTRACT: Cell size and the cell cycle are intrinsically coupled and abnormal increases in cell size are associated with senescence and permanent cell cycle arrest. The mechanism by which overgrowth primes cells to withdraw from the cell cycle remains unknown. We investigate this here using CDK4/6 inhibitors that arrest cell cycle progression during G0/G1 and are used in the clinic to treat ER+/HER2- metastatic breast cancer. We demonstrate that CDK4/6 inhibition promotes cellular overgrowth during G0/G1, causing p38MAPK-p53-p21-dependent cell cycle withdrawal. We find that cell cycle withdrawal is triggered by two waves of p21 induction. First, overgrowth during a long-term G0/G1 arrest induces an osmotic stress response. This stress response produces the first wave of p21 induction. Second, when CDK4/6 inhibitors are removed, a fraction of cells escape long term G0/G1 arrest and enter S-phase where overgrowth-driven replication stress results in a second wave of p21 induction that causes cell cycle withdrawal from G2, or the subsequent G1. We propose a model whereby both waves of p21 induction contribute to promote permanent cell cycle arrest. This model could explain why cellular hypertrophy is associated with senescence and why CDK4/6 inhibitors have long-lasting effects in patients.
INSTRUMENT(S): Liquid Chromatography MS -, Liquid Chromatography MS - negative - hilic
PROVIDER: MTBLS5868 | MetaboLights | 2025-10-24
REPOSITORIES: MetaboLights
| Action | DRS | |||
|---|---|---|---|---|
| Matrix_blank_1_neg.mzXML | Mzxml | |||
| Matrix_blank_2_neg.mzXML | Mzxml | |||
| Matrix_blank_3_neg.mzXML | Mzxml | |||
| Matrix_blank_4_neg.mzXML | Mzxml | |||
| Matrix_blank_5_neg.mzXML | Mzxml |
Items per page: 1 - 5 of 78 |

Molecular cell 20231116 22
Abnormal increases in cell size are associated with senescence and cell cycle exit. The mechanisms by which overgrowth primes cells to withdraw from the cell cycle remain unknown. We address this question using CDK4/6 inhibitors, which arrest cells in G0/G1 and are licensed to treat advanced HR+/HER2- breast cancer. We demonstrate that CDK4/6-inhibited cells overgrow during G0/G1, causing p38/p53/p21-dependent cell cycle withdrawal. Cell cycle withdrawal is triggered by biphasic p21 induction. T ...[more]